VR Adviser, LLC Q3 2020 Filing
Filed November 16, 2020
Portfolio Value
$511.2B
Holdings
22
Report Date
Q3 2020
Filing Type
13F-HR
All Holdings (22 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | TREURTRILLIUM THERAPEUTICS INC | 7,204,577 | $102.4B | 20.03% | |
| 2 | —CONSTELLATION PHARMACEUTICAL | 4,016,873 | $81.4B | 15.92% | |
| 3 | ALTALTIMMUNE INC | 4,500,000 | $59.4B | 11.62% | |
| 4 | —ATHIRA PHARMA INC | 1,521,623 | $28.1B | 5.50% | |
| 5 | SURFUSDSURFACE ONCOLOGY INC | 3,877,895 | $26.8B | 5.23% | |
| 6 | KROSKEROS THERAPEUTICS INC | 672,306 | $25.9B | 5.07% | |
| 7 | RLMDRELMADA THERAPEUTICS INC | 668,440 | $25.1B | 4.92% | |
| 8 | —HUMANIGEN INC | 2,332,516 | $24.8B | 4.86% | |
| 9 | CRDFCARDIFF ONCOLOGY INC | 1,271,985 | $18.0B | 3.53% | |
| 10 | IMV1EURIMV INC | 4,000,000 | $17.8B | 3.47% | |
| 11 | KURAKURA ONCOLOGY INC | 575,000 | $17.6B | 3.45% | |
| 12 | —MARINUS PHARMACEUTICALS INC | 1,192,883 | $15.3B | 3.00% | |
| 13 | TCE2CELLDEX THERAPEUTICS INC | 800,000 | $11.9B | 2.32% | |
| 14 | —METACRINE INC | 1,143,673 | $11.7B | 2.28% | |
| 15 | ALXOALX ONCOLOGY HOLDINGS INC | 300,000 | $11.3B | 2.21% | |
| 16 | —UNUM THERAPEUTICS INC | 4,355,273 | $10.2B | 1.99% | |
| 17 | SNDXSYNDAX PHARMACEUTICALS INC | 625,710 | $9.2B | 1.81% | |
| 18 | —FS DEVELOPMENT CORP-A | 500,000 | $5.6B | 1.10% | |
| 19 | —BCTG ACQUISITION CORP | 500,000 | $5.2B | 1.01% | |
| 20 | TSHATAYSHA GENE THERAPIES INC | 107,982 | $2.6B | 0.51% | |
| 21 | GRTXGALERA THERAPEUTICS INC | 51,653 | $467.0M | 0.09% | |
| 22 | —MEDICENNA THERAPEUTICS CORP | 92,453 | $383.0M | 0.07% |